Does neuroinflammation fan the flame in neurodegenerative diseases? by Frank-Cannon, Tamy C et al.
BioMed CentralMolecular Neurodegeneration
ssOpen AcceReview
Does neuroinflammation fan the flame in neurodegenerative 
diseases?
Tamy C Frank-Cannon1, Laura T Alto2, Fiona E McAlpine3 and 
Malú G Tansey*4
Address: 1Department of Veterinary Integrative Biosciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College 
Station, TX 77843, USA, 2Department of Physiology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA, 3Cancer 
Research UK London Research Institute, 44 Lincolns Inn Fields, WC2A 3PX, UK and 4Department of Physiology, Emory University School of 
Medicine, Atlanta, GA 30322, USA
Email: Tamy C Frank-Cannon - TFrank-Cannon@cvm.tamu.edu; Laura T Alto - laura.alto@utsouthwestern.edu; 
Fiona E McAlpine - fiona.mcalpine@cancer.org.uk; Malú G Tansey* - malu.tansey@emory.edu
* Corresponding author    
Abstract
While peripheral immune access to the central nervous system (CNS) is restricted and tightly
controlled, the CNS is capable of dynamic immune and inflammatory responses to a variety of
insults. Infections, trauma, stroke, toxins and other stimuli are capable of producing an immediate
and short lived activation of the innate immune system within the CNS. This acute
neuroinflammatory response includes activation of the resident immune cells (microglia) resulting
in a phagocytic phenotype and the release of inflammatory mediators such as cytokines and
chemokines. While an acute insult may trigger oxidative and nitrosative stress, it is typically short-
lived and unlikely to be detrimental to long-term neuronal survival. In contrast, chronic
neuroinflammation is a long-standing and often self-perpetuating neuroinflammatory response that
persists long after an initial injury or insult. Chronic neuroinflammation includes not only long-
standing activation of microglia and subsequent sustained release of inflammatory mediators, but
also the resulting increased oxidative and nitrosative stress. The sustained release of inflammatory
mediators works to perpetuate the inflammatory cycle, activating additional microglia, promoting
their proliferation, and resulting in further release of inflammatory factors. Neurodegenerative
CNS disorders, including multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease
(PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), tauopathies, and age-related
macular degeneration (ARMD), are associated with chronic neuroinflammation and elevated levels
of several cytokines. Here we review the hallmarks of acute and chronic inflammatory responses
in the CNS, the reasons why microglial activation represents a convergence point for diverse
stimuli that may promote or compromise neuronal survival, and the epidemiologic, pharmacologic
and genetic evidence implicating neuroinflammation in the pathophysiology of several
neurodegenerative diseases.
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Once considered an immune-privileged site because of
the presence of the blood brain barrier (BBB), it is now
clear that while peripheral immune access to the central
nervous system (CNS) is restricted and tightly controlled,
the CNS is capable of dynamic immune and inflamma-
tory responses to a variety of insults [1]. Infections,
trauma, stroke, toxins and other stimuli are capable of
producing an immediate and short lived activation of the
innate immune system within the CNS [2,3]. This acute
neuroinflammatory response includes activation of the
resident immune cells (microglia) resulting in a phago-
cytic phenotype and the release of inflammatory media-
tors such as cytokines and chemokines [4]. While an acute
insult may trigger oxidative and nitrosative stress, it is typ-
ically short-lived and unlikely to be detrimental to long-
term neuronal survival. Therefore, it is believed that an
acute neuroinflammatory response is generally beneficial
to the CNS, since it tends to minimize further injury and
contributes to repair of damaged tissue.
In contrast, chronic neuroinflammation is a long-stand-
ing and often self-perpetuating neuroinflammatory
response that persists long after an initial injury or insult.
Chronic neuroinflammation includes not only long-
standing activation of microglia and subsequent sus-
tained release of inflammatory mediators, but also results
in increased oxidative and nitrosative stress [4]. The sus-
tained release of inflammatory mediators works to perpet-
uate the inflammatory cycle, activating additional
microglia, promoting their proliferation, and resulting in
further release of inflammatory factors. Owing to the
chronic and sustained nature of the inflammation, there is
often compromise of the BBB which increases infiltration
of peripheral macrophages into the brain parenchyma to
further perpetuate the inflammation [1]. Rather than serv-
ing a protective role as does acute neuroinflammation,
chronic neuroinflammation is most often detrimental
and damaging to nervous tissue. Thus, whether neuroin-
flammation has beneficial or harmful outcomes in the
brain may depend critically on the duration of the inflam-
matory response.
Neurodegenerative CNS disorders, including multiple
sclerosis (MS), Alzheimer's disease (AD), Parkinson's dis-
ease (PD), Huntington's disease (HD), amyotrophic lat-
eral sclerosis (ALS), tauopathies, and age-related macular
degeneration (ARMD), are associated with chronic neu-
roinflammation and elevated levels of several cytokines
[5-8]. Neuropathological and neuroradiological studies
indicate that neuroinflammatory responses may begin
prior to significant loss of neuronal populations in the
progression of these diseases. While there is no evidence
to support a role for any particular cytokine in the direct
triggering of any of these neurodegenerative conditions,
cytokine-driven neuroinflammation and neurotoxicity
may modify disease progression in a number of these dis-
orders. For example, inflammatory challenges might act as
triggers to uncover pre-existing genetic vulnerabilities that
contribute to neuronal dysfunction and death. Alterna-
tively, viruses or bacteria might "prime" the immune sys-
tem to respond aberrantly to subsequent environmental
challenges. The purpose of this article is to review the evi-
dence that microglial activation represents a convergence
point for diverse external stimuli that promote neuronal
dysfunction and hasten neuronal death, and the epidemi-
ologic, pharmacologic and genetic evidence implicating
neuroinflammation in the pathophysiology of several
neurodegenerative diseases. If the available evidence sup-
ports a role for neuroinflammation in any of these dis-
eases, it may be possible to alter the course of disease
development in afflicted individuals with timely delivery
of anti-inflammatory therapy.
Microglia activation: convergence point for 
diverse stimuli that compromise neuronal 
survival
Microglia are the resident tissue macrophages in the cen-
tral nervous system and are the principle mediators of
inflammation. In the resting state, microglia display a
small cell soma and numerous branching processes (a
ramified morphology). In healthy brain tissue, these proc-
esses are dynamic structures that extend and retract sam-
pling and monitoring their microenvironment
(Nimmerjahn 2005, Raivich 2005). During the resting
state several key surface receptors are expressed at low lev-
els; these include the tyrosine phosphatase (CD) 45 (also
known as leukocyte common antigen), CD-14, and
CD11b/CD18 (Mac-1) (Kreutzberg 1996). In addition
cell surface receptor-ligand pairs such as CD200R/CD200
are present to maintain neuron-glia communication in
the CNS (Hock 2000, Cardona 2006).
In the presence of an activating stimulus, microglial cell-
surface receptor expression is modified and the cells
change from a monitoring role to one of protection and
repair (reviewed in [4,9]). In addition to up-regulation of
the key surface receptors mentioned above, there is up-
regulation of proteins such as CD1, lymphocyte function-
associated antigen 1 (LFA-1), intercellular adhesion mol-
ecule 1 (ICAM-1 or CD54), and vascular cell adhesion
molecule (VCAM-1 or CD106). Activated microglia
secrete a variety of inflammatory mediators including
cytokines (TNF, and interleukins IL-1β and IL-6) and
chemokines (macrophage inflammatory protein MIP-1α,
monocyte chemoattractant protein MCP-1 and interferon
(IFN) inducible protein IP-10) that promote the inflam-
matory state. The morphology of the cells changes from
ramified to amoeboid as they take on a phagocytic role.
These moderately active microglia are thought to performPage 2 of 13
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removing dying cells and cellular debris, and secreting
trophic factors that promote neuronal survival. Persistent
activation of brain-resident microglia may increase the
permeability of the BBB and promote increased infiltra-
tion of peripheral macrophages, the phenotype of which
is critically determined by the CNS environment [10].
Microglia are the critical convergence point for the many
diverse triggers that elicit an adaptive immune response
(Figure 1). Stroke, hypoxia, and trauma compromise neu-
ronal survival and indirectly trigger neuroinflammation as
microglia become activated in response to the insult in an
attempt to limit further injury. Infectious agents activate
microglia either through damage to infected cells or direct
recognition of foreign (viral or bacterial) proteins. Follow-
ing exposure to neurotoxins such as the mitochondrial
complex I inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP), the dopamine analog 6-hydroxy-
dopamine (6-OHDA), or the pesticide paraquat,
microglia become activated and primed. Microglial
responses to these toxins may contribute to neuronal dys-
function and eventually hasten neurodegeneration
(Czlonkowska et al., 1996; Kohutnicka et al., 1998; Liber-
atore et al., 1999; Dehmer et al., 2000; Vila et al., 2001).
In addition, genetic mutations that give rise to increased
production of toxic oligomeric, aggregated/truncated, or
oxidized protein species promote sustained activation of
microglia and may prime the immune system for aberrant
responses to subsequent insults. Regardless of the initiat-
ing factor, all of these external or internal stimuli have the
potential to trigger a self-perpetuating inflammatory
response that, if left unresolved, may contribute to death
of vulnerable neuronal populations.
Evidence of neuroinflammation and cytokine 
involvement in neurodegenerative diseases
Alzheimer's Disease (AD)
Although the etiology of sporadic AD in humans is
unknown, mutations in Amyloid Precursor Protein (APP)
or components of its processing machinery (β-secretase
and γ-secretase) result in overproduction of Aβ1-40 and 1-
42 peptides and are sufficient to cause disease [11-17].
Over 20 years ago, microglia were reported to localize to
amyloid plaques in AD brain [18] and since then, the
association between neuroinflammation and AD has
been extensively investigated [7,19-24] and reviewed
[19,25]. Human microglia display an activated phenotype
when they surround plaques [23] that includes upregula-
tion of Human Leukocyte Antigen-DR (HLA-DR) [18]. In
addition to producing cytokines and other pro-inflamma-
tory mediators [19,26], microglia have also been reported
to exert toxicity on neurons that have been pre-exposed to
low concentrations of Aβ42 via a CD14-dependent proc-
ess [27]. Although it is clear that not all microglia activa-
tion is injurious to neurons, it is becoming widely
accepted that a type of neurotoxic microglia phenotype
has a central role in the pathophysiology of AD.
While microglia can become activated after exposure to
fibrillary Aβ in vitro and are capable of phagocytosing it in
vitro [28-30], it has been reported that in the presence of
inflammatory cytokines or certain extracellular matrix
proteins, microglia cannot phagocytize Aβ [31]. This
observation has been used to support the idea that the
persistence and accumulation of amyloid plaques in vivo
may be a direct result of this inhibitory behavior exerted
by neuroinflammation. Moreover, numbers of IL-1α pos-
itive (i.e., pro-inflammatory) microglia are increased in
the cortical layers affected by plaque pathology in AD
patients [32]. Since microglia are found in large numbers
around neuritic amyloid plaques, but not diffuse in
human AD patients, and in mice transgenic for mutant
APP [33], it has been postulated that microglia play a role
in the conversion of diffuse to neuritic senile plaques but
not in the origin of diffuse plaques [34]. Specifically, post-
mortem analyses of microglia density in the neocortex of
three groups of nondemented individuals at different
stages of senile plaque formation versus AD patients
revealed that the mean density of microglia was highest in
the AD group and that microglia were associated with
neuritic plaques much more often than with diffuse
plaques Interestingly, individuals with some neuritic
plaques also had microglia within a greater proportion of
their diffuse plaques than individuals who only had dif-
fuse plaques. While these findings raise the possibility
that microglial activity may promote conversion of diffuse
plaques into neuritic plaques, an important caveat of this
study is that this conclusion is based on correlative obser-
vations postmortem and were not derived from a dynamic
in situ analysis of microglial activity around diffuse or neu-
ritic plaques.
The pro-inflammatory effect of Aβ deposition in brain has
been recapitulated in aged mice transgenic for a familial
AD mutation of APP, in which astrocytes and microglia
expressing Il-1β, IL-6 and TNF have been found surround-
ing amyloid plaques [35]. The bacterial endotoxin
lipopolysaccharide (LPS), a powerful inducer of inflam-
matory responses [36], exacerbates the appearance and
severity of AD pathology in the APPV717F transgenic
mouse [37], the APPswe transgenic mouse [38], and the
triple-transgenic (3xTgAD) mouse [39]. In addition, the
Transforming Growth Factor-β (TGF-β) cytokine family
increases Aβ accumulation in the cerebral blood vessels of
mice transgenic for human APP and is upregulated in
blood vessels of human patients with Cerebral Amyloid
Angiopathy (CAA) [40]. Co-addition of TGF-β1, 2 and 3
isoforms with Aβ causes increased Aβ accumulation in
organotypic hippocampal slices [41]. Together, thesePage 3 of 13
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Neuroinflammation can precede and contribute to neuronal dysfunction and degenerationFig re 1
Neuroinflammation can precede and contribute to neuronal dysfunction and degeneration. Divergent initiating 
triggers directly or indirectly converge to activate microglia (stained here with an antibody against F4/80) from a ramified/rest-
ing state to an ameboid-shape/activated state, initiating a self-propelling cycle of neuroinflammation and chronic over-produc-
tion of inflammatory mediators. These mediators impact susceptible neuronal populations in the CNS and contribute to their 
demise within the context of each neurodegenerative disorder. The progressive loss of neurons that characterizes these disor-
ders further contributes to generation of debris and keeps microglia activated indefinitely maintaining microglia in an activated 
state long-term.
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microglia and plaque deposition and the ability of certain
chronic inflammatory stimuli to exacerbate and accelerate
amyloid-associated pathology. The emerging idea is that
an inflamed CNS environment may influence the ability
of microglia to contribute to plaque deposition rather
than plaque removal, strongly suggesting that the micro-
environment of the brain can influence whether microglia
perform beneficial or deleterious functions in pathophys-
iological states.
While the role of inflammatory responses in AD are just
beginning to be understood, there is little dispute that
inflammatory mediators may represent both potentially
useful biomarkers and targets for drug development.
Cyclooxygenase 2 (COX2), a pro-inflammatory protein
that is one of the targets of non-steroidal anti-inflamma-
tory drugs (NSAIDs), and its homolog COX-1 [42], are
elevated in AD brains [43]. Serum levels of the acute phase
protein α1-antichymotrypsin, which is upregulated by
injury, trauma and infection, are also significantly higher
in AD patients than healthy controls [44]. And clinically,
a proteomic study of plasma from control subjects,
patients with Mild Cognitive Impairment (MCI) and
patients with AD suggested that dysregulated systemic
immune responses are present in patients who progress
from MCI and go on to develop AD, raising the interesting
possibility that this inflammation "communicome" may
serve as signature for early detection of the disease [45].
Not only is neuroinflammation believed to be one of the
earliest consequences of Aβ deposition, it has been shown
to accelerate neurodegeneration and contribute to pro-
gression of pathology [46]. Epidemiological studies sug-
gest a link between chronic use of non-steroidal anti-
inflammatory drugs (NSAIDs) and reduced risk for AD. In
a study of siblings who all eventually developed AD, reg-
ular use of NSAIDs delayed the onset of AD and reduced
the risk of AD with each year of use [47]. Participants in
the Baltimore Longitudinal Aging Study also exhibited a
reduced risk for AD with the use of NSAIDs, with those
patients who had taken NSAIDs for more than 2 years
showing the most reduction in AD risk [48]. Comparison
of brains of aged but cognitively normal patients who
used NSAIDs chronically with that of cognitively normal
patients who did not use NSAIDs revealed no changes in
the appearance of senile plaques, but a 3-fold decrease in
the number of activated microglia in the brains of chronic
NSAID users [49]. Most recently in what is the largest and
longest duration epidemiological study to date, long-term
(> 5 yrs) NSAID use, in particular ibuprofen, was shown
to be protective against development of AD [50]. These
findings suggest that the protection afforded by chronic
NSAID use in the studies of AD patients may in part be
derived by attenuation of microglia activation. Consistent
with the epidemiological findings on ibuprofen, chronic
ibuprofen administration in aged transgenic mice reduced
the number and area of amyloid plaques, as well as the
numbers of activated microglia [51], and administration
of R-flurbiprofen rescued deficits in hippocampal and
medial temporal lobe-dependent memory and learning
[52]. However, thus far, clinical trials using systemic
administration of NSAIDs have yielded mixed or incon-
clusive results [53-55], reflecting the need to identify and
target the key inflammatory mediators that promote amy-
loid-associated neuropathology.
However, it is important to note that the presence inflam-
matory responses may also be necessary to prevent amy-
loid-associated neurotoxicity. For example, the activation
of complement factor C3, the central component of the
complement system and a key inflammatory protein may
be necessary for plaque clearance by microglia in the AD-
afflicted brain [56,57]. In addition, an important compo-
nent of any inflammatory response is the activation of
anti-inflammatory loops that serve to limit and resolve
the initial inflammatory response. The Peroxisome Prolif-
erator-Activated Receptor-γ (PPARγ), a nuclear receptor
which is activated by metabolites of prostaglandins gener-
ated by the COX enzymes and by certain NSAIDs, is
upregulated in concert with the COX enzymes in AD brain
[42]. As such, PPARγ activation exerts an anti-inflamma-
tory effect, and PPARγ agonists have been shown to
inhibit the production of cytokines and pro-inflammatory
mediators in response to Aβ [58]. In addition, there
appears to be a feedback signaling loop between Aβ and
IL-1β: Aβ can induce the production of IL-1β [7], and the
presence of IL-1β greatly increases the secretion of
cytokines IL-6 and IL-8 in response to Aβ by astrocytes; in
the other direction, IL-1α and IL-1β both upregulate the
expression of APP, thus probably upregulating the pro-
duction of Aβ [59]. The ratio of the pro-inflammatory
cytokine IL-1β to the anti-inflammatory cytokine IL-10 is
drastically elevated in the serum of AD patients, giving
these patients a definite pro-inflammatory profile [60].
Increases in levels of IL-1β have been correlated with
decreases in LTP in the hippocampus, showing that the
cytokine itself may impair memory [61]. Other evidence,
however, suggests that IL-1β may not be driving AD path-
ogenic processes. For example, functional inhibition of IL-
1β signaling in mice by genetic ablation of the IL1 recep-
tor [62] or by infusion of IL-1ra did not modulate Aβ dep-
osition. In addition, IL-1β was recently shown to
upregulate the α-secretase TACE, thus increasing non-
amyloidogenic cleavage of APP and decreasing Aβ pro-
duction [63]. Therefore, while it may participate in neu-
roinflammatory responses in AD brain by activating
microglia to secrete other inflammatory mediators, IL-1β
is not required to drive Aβ deposition and may in fact acti-
vate non-amyloidogenic pathways.Page 5 of 13
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AD has been the active or passive immunization against
Aβ. Immunizing PDAPP mice with Aβ42 prevented or
reduced the progression of AD pathology in these mice,
depending on whether the immunization took place
before or after the development of plaque pathology [64].
Vaccination with Aβ peptides also ameliorated cognitive
deficits in mice transgenic for a familial AD (FAD) muta-
tion in APP and an FAD mutation in PS1 [65]. As an alter-
native delivery route, intranasal administration of Aβ
peptides reduced amyloid deposition in AD mouse mod-
els [66,67]. Aβ vaccinations were also found successful in
reducing Aβ levels in two non-human primates, the rhe-
sus monkey [68] and the Caribbean vervet [69]. A clinical
trial of Aβ42 vaccinations was undertaken by Elan Phar-
maceuticals in AD patients, and the immunizations
resulted in significant clearance of Aβ and plaque removal
in some of the patients [70,71], as well as a slowing of the
cognitive decline in patients who produced antibodies
against the peptide [72]. Unfortunately, the immuniza-
tion also resulted in dangerous T-lymphocyte meningoen-
cephalitis in some patients, causing the arrest of these
trials [70,73]. Passive immunization of PDAPP mice
peripherally infused with antibodies that recognize aggre-
gated Aβ in neuritic plaques rapidly increased microglial
clustering around plaques detectable by in vivo multi-
photon microscopy [74] and reduced plaque burden and
AD pathology in PDAPP mice [75]. Administration of
antibodies specifically directed against oligomers of Aβ
improved learning and memory in Tg2576 mice [76].
Therefore, passive immunization may be a safer approach
in AD patients. In addition, there is strong evidence that
using shorter Aβ peptides is safer than using full-length
Aβ40 or 42 as the immunogen [77]. In short, Aβ immuno-
therapy holds promise but will need to be made safer and
more effective in its ability to generate good antibody tit-
ers in the elderly [78]. If these novel immunogens can
enhance Aβ antibody generation without the adverse
events seen in the earlier clinical trial, neuroimmune
modulation by vaccination may become an effective way
to prevent AD.
Parkinson's Disease (PD)
Classically, the neuropathological hallmark of idiopathic
PD includes the presence of α-synuclein-positive inclu-
sions in the cell body (Lewy bodies) and processes (Lewy
neurites) of specific neurons of the brainstem and a classic
motor phenotype resulting from substantial loss of
dopaminergic neurons from the substantia nigra pars
compacta (SNpc) (reviewed in [79]). A number of studies
have confirmed the presence of inflammatory mediators
(including TNF, IL-1β, IL-6, and IFNγ) in the cerebrospi-
nal fluid (CSF) of patients with PD as well as in the post-
mortem SNpc in PD patient brains [80-84]. Significantly
elevated levels of TNF mRNA and protein can be detected
in the rodent midbrain substantia nigra within hours of in
vivo administration of two neurotoxins widely used to
model parkinsonism in rodents, 6-hydroxydopamine (6-
OHDA) [8] and 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-
ridine (MPTP) [85-87]. Consistent with a role of TNF in
contributing to dopaminergic neuron death in chronic
parkinsonism, plasma TNF levels were shown to remain
elevated in MPTP-treated non-human primates one year
after administration of the neurotoxin [88]. In contrast,
studies involving mice deficient in TNF or both TNF recep-
tors have yielded conflicting results in that one group
reported lack of TNF receptors altered dopamine metabo-
lism and reduced survival of dopaminergic terminals [86]
and other groups reported TNF-deficient mice to have
reduced sensitivity to MPTP-induced neurotoxicity
[85,87]. Loss of TNF receptors versus TNF ligand during
development might alter the behavior of microglia or
other immune cell populations and contribute to conflict-
ing outcomes in these studies. In addition, the use of dif-
ferent MPTP lesioning regimens in these two studies make
it difficult to compare them directly.
Additional evidence that inflammation (and in particular
TNF) is involved in nigral DA neuron degeneration comes
from two endotoxin rat models. In the first model chronic
low dose lipopolysaccharide (LPS) infusion into SNpc of
rats results in delayed, selective and progressive loss of
nigral DA neurons [89]. In the second model exposure of
pregnant rats to LPS and thus, in utero exposure of
embryos to the endotoxin, caused a loss of DA neurons in
postnatal brains [90]. Most importantly, chronic infusion
of dominant negative TNF inhibitor proteins into SNpc of
adult rats protected nigral DA neurons from LPS and 6-
OHDA induced degeneration [91] as did a single nigral
injection of a lentivirus encoding DN-TNF in 6-OHDA
hemiparkinsonian rats [92]. Given that TNF receptors are
expressed in nigrostriatal dopamine neurons [93,94] and
these neurons are selectively vulnerable to TNF-induced
toxicity [95-99], these early genetic studies and the more
recent chronic inflammation models of PD strongly
implicate TNF and its downstream targets in neurotoxin-
and endotoxin-induced loss of nigral DA neurons. How-
ever, because it is clear that the permeability of the BBB
increases with age increases the likelihood of peripheral
immune cell infiltration into the CNS, TNF produced by
brain-resident microglia may not be acting alone in medi-
ating DA neuron cell death but in concert with other cir-
culating neurotoxic factors to increase the inflammatory
susceptibility of nigral DA neurons and development of
PD.
Another link between inflammation and neurodegenera-
tion comes from studies of single nucleotide polymor-
phisms that are associated with over-production of
cytokines, chemokines and acute phase proteins. ThesePage 6 of 13
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individuals affected with PD and may confer increased
susceptibility for the disease [100-104]. However, most of
these findings have not been replicated in independent
studies and a meta-analysis of multiple association stud-
ies is needed to assess the overall genetic effect of cytokine
gene polymorphisms on neurodegenerative disease.
Lastly, the advent of technologies such as positron emis-
sion tomography (PET) brain scans has enabled clinicians
to image microglial activation in living patients. Recent
PET studies confirm that patients with idiopathic PD have
markedly elevated microglia activation in the pons, basal
ganglia, striatum, and frontal and temporal cortical
regions irrespective of the number of years with the dis-
ease compared to healthy age-matched controls [81]. Per-
sistent activation of the abundant number of microglia in
the midbrain region are likely the direct result of elevated
levels of cytokines acting in an autocrine manner to
potentiate inflammatory responses (e.g., auto-amplifica-
tion of reactive oxygen species, nitric oxide, and superox-
ide radicals to form highly oxidizing peroxynitrite
species)[7,105-108]. Given that DA neurons in the mid-
brain have an inherently elevated oxidative intracellular
environment as a result of oxidation reactions required for
the synthesis of the neurotransmitter dopamine, chronic
neuroinflammation is likely to further enhance oxidative
stress, hasten dysfunction, and eventually lead to death of
DA neurons.
Huntington's Disease (HD)
Huntington's disease (HD) is an autosomal dominant
neurodegenerative disorder that has been linked to muta-
tions in the huntingtin gene (htt) [109]. CAG repeat expan-
sions in the htt gene result in an increased number of
glutamine residues in the huntingtin protein (poly-
glutamine expansion). Mutant htt causes degeneration of
neurons, predominately in the caudate putamen and cor-
tex, causing HD patients to suffer from uncontrolled
movements, emotional disturbances and dementia. While
the mechanism by which mutant htt causes neurodegen-
eration remains obscure, evidence supporting inflamma-
tion as an important player in HD is accumulating.
Recent studies have demonstrated that inflammation
appears both peripherally and in the central nervous sys-
tem (CNS) during the progression of HD and HD-like
pathology. The R6/2 mouse model of HD displays
increased serum levels of IL-6 and in downstream IL-6
effectors, such as alpha-2-macroglobulin (A2 M) and
complement components [110]. In the CNS, microarray
profiling of several brain regions from HD patients and
controls revealed increased gliosis and expression of
inflammation-related genes, including GFAP and comple-
ment proteins. Increases were most pronounced in the
caudate putamen where brain pathology is most severe in
HD patients [111]. Increases in labeling of complement
proteins in neurons and astrocytes and a 2-5 fold increase
in activators and regulators of the classical complement
pathway have also been detected in human HD brains by
RT-PCR [112]. Lastly, clinical plasma samples from HD
gene carriers contain increased levels of pro-inflammatory
cytokines involved in the innate immune response, such
as IL-6 [113].
A number of studies indicate that the altered immune pro-
file in HD occurs before onset of clinical HD symptoms,
suggesting that striatal and cortical neurodegeneration
could be exacerbated by inflammation. For example,
plasma samples from HD gene carriers contain increased
levels of pro-inflammatory cytokines involved in the
innate immune response before the onset of clinical
symptoms and investigators have been able to discrimi-
nate controls from presymptomatic HD mutation carriers
by measuring the levels of 3 cytokines, IL-5, IL-6, and IL-
10 in plasma [113]. In brains of mutant htt carriers,
microglia are activated before onset of symptoms and
increased microglial activation correlates with an
increased chance of developing HD symptoms in 5 years
[114]. Once symptoms have manifested, microglial acti-
vation correlates with disease severity [115,116]. In the 3-
nitroproprionic acid neurotoxin model of HD in rats,
treatment with Celastrol, an anti-inflammatory and anti-
oxidant compound derived from plants, reduced striatal
lesion volume [117], indicating that controlling an
inflammatory response could be therapeutically benefi-
cial as HD progresses. However, treatment with acetylsal-
icylate or rofecoxib, anti-inflammatory drugs commonly
used in the clinic, was not neuroprotective in either the
R6/2 or N171-82Q transgenic mouse models of HD
[118].
Since mutant htt is known to cause a number of deleteri-
ous effects in cells, it is possible that increased inflamma-
tion in HD brains is simply the CNS response to neuronal
death that is a direct result of mutant htt toxicity. How-
ever, several studies point to the intriguing possibility that
mutant htt might itself trigger an inflammatory response,
the by-products of which could cause degeneration of
neurons. For example, inflammation in HD could be a
result of overactive immune cells, such as macrophages in
the periphery and microglia in the CNS. Monocytes from
HD patients secrete abnormally high levels of the pro-
inflammatory cytokine IL-6 in response to a combination
of interferon-gamma (IFN-γ) and LPS. Microglia from
YAC128 and R6/2 mouse models of HD respond in a sim-
ilar overactive manner [113]. Mutant htt is found in glial
nuclei where it can act to alter gene expression, probably
because of its aberrant interactions with transcription fac-
tors that are made possible by glutamine expansion-
related conformational changes in the htt protein [119].Page 7 of 13
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complex, the major kinase that leads to phosphorylation-
induced degradation of IκBs, leading to increased translo-
cation of NF-κB dimers to the nucleus in mouse striatal
cells [120]. Since NF-κB can promote expression of IL-6
and other inflammatory cytokines in glia, such an interac-
tion provides a candidate mechanism by which mutant
htt could alter the activity of immune cells leading to an
abnormally robust inflammatory response.
The presence of increased inflammatory mediators in the
periphery and in the CNS beg the question of whether
CNS inflammation "leaks" into the periphery to alter the
peripheral immune profile or whether inflammation is
triggered in the periphery and immune modulators are
allowed to cross the BBB to trigger or contribute to a cen-
tral inflammatory response. Another possibility is that an
inflammatory response is triggered in the periphery and
the CNS by an analogous mechanism. These alternatives
are just beginning to be explored.
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) involves a progressive
degeneration of motor neurons in the brain and spinal
cord. While most cases are sporadic in origin, approxi-
mately 5-10% of the cases are caused by an autosomal
dominant mutation. ALS is typically fatal within 5 years of
diagnosis due to a progressive, generalized paralysis that
eventually affects the muscles of respiration, causing res-
piratory failure. Areas where degenerating motor neurons
are present in both ALS patients and mouse models are
marked by the presence of cytokines and immune cells,
including T cells, activated microglia, and astrocytes
[121,122]. In addition PET imaging of ALS patients
showed an increase in activated microglia in the motor
cortex that correlates with upper motor neuron symptoms
[123]. In some ALS disease models the presence of
immune cells precedes the disease phenotype [124], and
the chemokine MCP-1, a potent chemotactic stimulus for
microglia [125] is elevated in the CSF of ALS patients
[126], suggesting that neuroinflammation could contrib-
ute to disease progression. In addition, the levels of gen-
eral markers of inflammation in the serum of ALS patients
correlate positively with the severity of their disability
[127]. While multiple genetic loci have been identified as
causal in familial forms of ALS, 20% of familial cases
involve a gain of function mutation in Cu/Zn superoxide
dismutase I (SOD1) [128]. In addition to the well-estab-
lished role of SOD1 as a critical anti-oxidant enzyme, evi-
dence suggests that part of its normal function is to protect
against protein aggregation, a phenomenon that is known
to hasten neuronal degeneration. Nevertheless, several
studies have suggested that SOD1 mutations in neurons
alone are insufficient to cause ALS and that dysfunction in
support glia may contribute to disease development and
progression [129-132]. For example, ablating microglial
expression of mutant SOD 1 (mSOD1) or transplanting
bone marrow from wild-type mice into mSOD1 trans-
genic mice increases the life span of mutant mice
[133,134], suggesting that SOD1 mutations may indi-
rectly contribute to neuronal death by affecting glial
rather than neuronal function. Consistent with this idea,
mSOD1 mice stimulated with LPS secrete more inflam-
matory mediators, including TNF [135], MCP-1, TGF-
β[121] and IFN-γ [136], than control mice. Importantly,
levels of TNF correlate with severity of motor neuron loss
in mouse models of the disease [137,138] and both TNF
receptors are elevated in the serum of ALS patients [139].
In pre-clinical mouse models, certain anti-inflammatory
treatments aimed at suppressing microglia activation have
been shown to increase the life expectancy of mice
expressing human mutant SOD1 by more than 30%
[140]. Anti-inflammatory treatments also prevented neu-
rotoxicity when the CSF of ALS patients was applied to rat
spinal cord motor neurons [141]. Although a generalized
neuroinflammatory response may be driving progressive
loss of motor neurons, not all inflammatory mediators
have been strongly implicated in ALS. For instance, IL-1β
may not be critical to ALS pathogenesis as genetic deletion
of IL-1β does not change the lifespan or rate of motor neu-
rodegeneration in mSOD-1 mice [142].
Summary and Conclusion
It is becoming increasingly evident that neuroinflamma-
tion plays a crucial role in the development and progres-
sion of many neurodegenerative diseases. Glia and in
particular microglia are central to mediating the effects of
neuroinflammation. While neuroinflammation and
microglia provide an attractive therapeutic target in the
treatment and prevention of neurodegenerative diseases
investigators face several challenges ahead (Appendix 2)
which must be overcome before one can advocate in favor
of large-scale anti-inflammatory trials in the clinic. Some
of these include developing approaches to improve the
access of drugs to CNS tissue as well as developing thera-
pies that maintain or optimize the beneficial effects of
neuroinflammation while eliminating or minimizing its
detrimental effects.
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Appendix 1: Key Observations
1. Neurodegenerative diseases are associated with
signs of chronic neuroinflammation
2. A variety of initiating triggers (some as yet
unknown) associated with the different neurodegen-
erative disorders converge at a common intersection
point - activation of microglia.
3. While the initial neuroimmune response may be
aimed at limiting the disease process, chronic neuroin-
flammation driven by persistent microglia activation
is likely to aid in the progression of the disease and the
hastening of neuronal demise.
4. How the inflammatory response affects specific
neuronal and glial populations and contributes to spe-
cific neurodegenerative diseases remains a critical and
unanswered question.
Appendix 2: Critical challenges involved in 
developing neuroprotective anti-inflammatory 
therapeutic strategies
1. Identify internal and external factors that trigger
chronic neuroinflammatory responses, with a focus on
how acute immune responses become chronic.
2. Identify inflammatory mediators that compromise sur-
vival of specific neuronal populations.
3. Develop therapeutic compounds that cross the blood
brain barrier (BBB)
4. Selectively target destructive inflammatory mediators
without compromising beneficial survival-promoting
effects and overall immune function.
5. Develop inclusion and exclusion criteria for human
subjects to be enrolled in clinical trials taking into account
their immune status.
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